-
NOVITÀ
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
Leggi di più » -
NOVITÀ
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
Leggi di più » -
NOVITÀ
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Leggi di più » -
NOVITÀ
-
Newsletter
-
NOVITÀ
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
Leggi di più » -
Member News
Iranian Blood Transfusion Organization Newsletter – December 2020
The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Leggi di più » -
NOVITÀ
Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director
by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…
Leggi di più » -
NOVITÀ
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease
Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…
Leggi di più » -
TIF News (IT)
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
Leggi di più »
